Activate and resist: L576P-KIT in GIST

Molecular Cancer Therapeutics

Volumn 8, Issue 9, 2009, Pages 2491-2495

  Conca, Elena ^a   Negri, Tiziana ^a   Gronchi, Alessandro ^a   Fumagalli, Elena ^a   Tamborini, Elena ^a   Pavan, Giovanni Maria ^b   Fermeglia, Maurizio ^b   Pierotti, Marco A ^a   Pricl, Sabrina ^b   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR; SUNITINIB;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER TISSUE; CASE REPORT; COMPUTER MODEL; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; TREATMENT RESPONSE; TUMOR REGRESSION; WILD TYPE;

AGED; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 70349487536     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0662     Document Type: Article

References (20)

1. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-3825
2. Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 2006;23:91-102. (Pubitemid 44692417)
3. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumors. Histopathology 2008;53:245-266
4. Miselli FC, Casieri P, Negri T, et al. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clin Cancer Res 2007;13:2369-2377 (Pubitemid 46698586)
5. Perrone F, Da Riva L, Orsenigo M, et al. PDGFRA, PDGFRB, EGFR and downstream signalling activation in malignant peripheral nerve sheath tumour. Neuro Oncol 2009. Epub Feb 26 2009.
6. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-4190 (Pubitemid 40791584)
7. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-4774 (Pubitemid 46630941)
8. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008;216:64-74.
9. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128:270-279 (Pubitemid 40431080)
10. Lasota J, vel Dobosz AJ, Wasag B, et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest 2007;87:1029-1041
11. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007;121:257-264
12. Frost D, Lasota J, Miettinen M. Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Vet Pathol 2003;40:42-54. (Pubitemid 38406113)
13. Ma Y, Longley BJ, Wang X, et al. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 1999;112:165-170 (Pubitemid 29061971)
14. Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004;23:3999-4006. (Pubitemid 38747928)
15. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-481 (Pubitemid 43166056)
16. Case DA, Darden TA, Cheatham TE III, et al. AMBER 9. San Francisco. San Francisco: University of California; 2006.
17. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-kit tyrosine kinase. J Biol Chem 2004;279:31655-31663
18. Pricl S, Fermeglia M, Ferrone M, et al. T315I-mutated Bcr-Abl in chronic myeloid leucemia and imatinib: insights from a computational study. Mol Cancer Ther 2005;4:1167-1174 (Pubitemid 41149564)
19. Negri T, Pavan GM, Virdis E, et al. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense. J Natl Cancer Inst 2009;101:194-204.
20. Srinivasan J, Cheatham TE III, Cieplak P, et al. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J Am Chem Soc 1998;120:9401-9409 (Pubitemid 28452628)